Cidara Scores $339M BARDA Boost for Universal Flu Drug CD388
Cidara Therapeutics has secured a significant boost for its influenza drug CD388. The company received an award worth up to $339M from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate domestic supply options and expand commercial capacity.
The multi-year agreement, which includes a Base contract and Option periods, provides initial funding of $58M over 24 months. This will support onshoring CD388 manufacturing and clinical trials. The award follows positive top-line results from Cidara's Phase 2b NAVIGATE trial for CD388, announced in June 2025. If exercised, Option periods could fund up to $281M, supporting additional studies for a potential Biologics License Application (BLA) submission.
CD388, an investigational drug-Fc conjugate, is designed to provide universal protection against all strains of seasonal and pandemic influenza with a single administration. Cidara Therapeutics is developing this novel drug using its proprietary Cloudbreak platform, with CD388 as its lead candidate.
The BARDA award, totaling up to $339M, will enable Cidara to advance CD388's development and manufacturing. Following successful clinical trials, this could lead to a Biologics License Application submission, potentially bringing a universal influenza protection drug to market.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
